• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Erythroid Enhancer of BCL11A Gene May Determine Fetal Hemoglobin Levels

October 25, 2013

A study published in the journal Science reveals that an erythroid enhancer of the BCL11A gene may be essential for determining fetal hemoglobin (HbF) levels. Researchers characterized common genetic variations in the BCL11A gene that were associated with elevated HbF levels, showing that these polymorphisms resided within a tissue- and developmental stage-specific enhancer. Genome engineering demonstrated that the enhancer is required for BCL11A expression within erythroid, but not within B-lymphoid cells. The BCL11A enhancer may serve as a potential genome-specific target to treat β-hemoglobinopathies.

 

Reference

1.    Bauer DE, Kamran SC, Lessard S, Xu J, Fujiwara Y, Lin C, Shao Z, Canver MC, Smith EC, Pinello L, Sabo PJ, Vierstra J, Voit RA, Yuan GC, Porteus MH, Stamatoyannopoulos JA, Lettre G, Orkin SH. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 2013;342: 253-7

Filed Under

  • News
  • Special Transfusion Situations

Recommended

  • ASFA Issues Updated Recommendations

  • Red Blood Cells Stored for More Than 35 Days are Safe

  • High Variability in ICU Transfusion Practices Globally

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • AABB Guidelines Recommend Liberal RBC Transfusion for Patients with Acute Myocardial Infarction

  • Artificial Intelligence to Predict Immunogenicity of Amino Acid Substitutions of Blood Group Antigens

  • Transfusion-related Alpha-Gal Syndrome

  • 2024 Serious Hazards of Transfusions (SHOT) Report in the U.K.

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley